Roche halts en­roll­ment in a PhII com­bo study of Tecen­triq and Cotel­lic in wake of sev­er­al pa­tient deaths

A string of deaths in a co­hort of colon can­cer pa­tients tak­ing a com­bi­na­tion of Roche’s PD-L1 check­point Tecen­triq with Ex­elix­is’ MEK in­hibitor Cotel­lic forced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER